Table 4.
Hormone-related NIH registered clinical trials at Clinicaltrials.gov
| NCT number | Start date | Results | Title | Study | |
|---|---|---|---|---|---|
| NCT03015701 | Aug-92 | Southwest Oncology Group∣National Cancer Institute (NCI) | Completed | S9005 mifepristone in meningioma | Drug: Mifepristone∣Other: Placebo |
| NCT00006368 | Jan-98 | Novartis Pharmaceuticals∣Novartis | Completed | Yttrium Y 90 SMT 487 in treating patients with refractory or recurrent cancer | Radiation: yttrium Y 90-edotreotide |
| NCT00049023 | Jan-02 | O’Dorisio, M S∣National Cancer Institute (NCI)∣University of Iowa | Completed | Radiolabeled octreotide in treating children with advanced or refractory Solid tumors | Radiation: 90Y-DOTA-tyr3-OCTREOTIDE |
| NCT00813592 | Nov-08 | University of Utah∣Novartis | Terminated | Phase II study of SOM230 in patients with recurrent or progressive meningioma | Drug: SOM230B |
| NCT00859040 | Mar-09 | Patrick Y. Wen, MD∣Brigham and Women’s Hospital∣Massachusetts General Hospital∣Beth Israel Deaconess Medical Center∣Memorial Sloan Kettering Cancer Center∣Wake Forest University Health Sciences∣Duke University∣Cedars-Sinai Medical Center∣Northwestern University∣Novartis∣Dana-Farber Cancer Institute | Completed | Monthly SOM230C for recurrent or progressive meningioma | Drug: SOM230C |
| NCT02194452 | Sep-13 | Sue O’Dorisio∣National Cancer Institute (NCI)∣Ride for Kids∣University of Iowa | Withdrawn | Efficacy of 68Ga-DOTATOC positron emission tomography (PET) CT in children and young adults with brain tumors | Radiation: gallium Ga 68-edotreotide∣Procedure: positron emission tomography∣Procedure: computed tomography∣Other: laboratory biomarker analysis |
| NCT02333565 | Jan-15 | Assistance Publique Hopitaux De Marseille | Unknown status | Combination of everolimus and octreotide LAR in aggressive recurrent meningiomas | Drug: Everolimus∣Drug: Octreotide |
| NCT03013387 | Jan-17 | Sue O’Dorisio∣National Institutes of Health (NIH)∣National Cancer Institute (NCI)∣University of Iowa | Withdrawn | Dosimetry guided PRRT with 90Y-DOTA-TOC | Radiation: 90Y-DOTA-3-tyr-Octreotide∣Procedure: Positron Emission Tomography (PET) whole body scan∣Drug: Amino Acids |
| NCT03001349 | 16-May-17 | M.D. Anderson Cancer Center∣National Cancer Institute (NCI) | Terminated | 68Ga-DOTA-TOC PET/CT in imaging participants with neuroendocrine tumors | Procedure: Computed Tomography∣Drug: Gallium Ga 68-Edotreotide∣Procedure: Positron Emission Tomography |
| NCT03273712 | 29-Sep-17 | Sue O’Dorisio∣National Institutes of Health (NIH)∣National Cancer Institute (NCI)∣University of Iowa | Unknown status | Dosimetry-guided, peptide receptor radiotherapy (PRRT) With 90Y-DOTA-tyr3-octreotide (90Y-DOTATOC) | Radiation: 90Y-DOTA tyr3-Octreotide∣Diagnostic Test: 68Ga-DOTATOC PET Positron Emission Tomography (PET) whole body scan∣Drug: Amino Acids |
| NCT03936426 | 9-Jul-18 | Clarity Pharmaceuticals Ltd | Completed | Peptide receptor radionuclide therapy administered to participants with meningioma with 67Cu-SARTATE | Drug: Cu-64 SARTATE and Cu-67 SARTATE |
| NCT03583528 | 11-Jul-18 | British Columbia Cancer Agency | Recruiting | DOTATOC PET/CT for imaging NET patients | Diagnostic Test: 68Ga-DOTATOC PET/CT∣Diagnostic Test: 18F-FDG PET/CT |
| NCT03953131 | 10-Jan-19 | M.D. Anderson Cancer Center∣National Cancer Institute (NCI) | Recruiting | Gallium Ga 68-DOTATATE PET/CT in predicting tumor growth in patients with meningiomas | Procedure: Computed Tomography∣Radiation: Gallium Ga 68-DOTATATE∣Procedure: Positron Emission Tomography |
| NCT04109404 | 25-Feb-19 | University Hospital, Brest | Completed | Meningiomas and treatment with CYPROTERONE ACETATE or progestin | Meningiomas and Treatment with CYPROTERONE ACETATE or Progestin |
| NCT03971461 | 15-May-19 | NYU Langone Health | Recruiting | Phase II study of 177Lu-DOTATATE radionuclide in adults with progressive or high-risk meningioma | Drug: Lutathera |
| NCT04081701 | 4-Sep-19 | Weill Medical College of Cornell University∣Novartis Pharmaceuticals | Recruiting | 68-Ga DOTATATE PET/MRI in the diagnosis and management of somatostatin receptor positive CNS tumors | Diagnostic Test: Ga68-DOTATATE-PET/MRI |
| NCT04082520 | 10-Mar-20 | Mayo Clinic∣National Cancer Institute (NCI) | Recruiting | Lutathera for the treatment of inoperable, Progressive meningioma after external beam radiation therapy | Radiation: Gallium Ga 68-DOTATATE∣Drug: Lutetium Lu 177 Dotatate∣Procedure: Magnetic Resonance Imaging∣Procedure: Positron Emission Tomography∣Other: Quality-of-Life Assessment∣Other: Questionnaire Administration |
| NCT04298541 | 18-Mar-21 | Weill Medical College of Cornell University∣Cornell University | Recruiting | Direct comparison of Ga-68-DOTATATE and Ga-68-DOTATOC | Drug: Ga-68-DOTATATE∣Drug: Ga-68-DOTATOC |
| NCT04997317 | 21-Apr-21 | University Hospital, Basel, Switzerland∣Swiss Cancer League | Recruiting | Treatment of recurrent or progressive meningiomas with the radiolabelled somatostatin antagonist 177Lu-satoreotide | Drug: 177Lu-DOTA-JR11 (Phase 0); Cycle 1 and Cycle 2 (cross-over)∣Drug: 177Lu-DOTATOC (Phase 0); Cycle 1 and Cycle 2 (cross-over), Cycle 3 and 4∣Drug: 177Lu-DOTA-JR11 (Phase I/II) |
| NCT04372095 | 6-Jul-21 | Assistance Publique—Hospitaux de Paris | Recruiting | Androcur (cyproterone acetate) and meningioma development: a genotype-environment association study | Procedure: oral smears |
| NCT05278208 | 25-May-22 | Ralph Salloum∣Children’s Hospital Medical Center, Cincinnati∣Nationwide Children’s Hospital | Not yet recruiting | Lutathera for treatment of recurrent or progressive high-grade CNS tumors or meningiomas expressing SST2A2 | Drug: LUTATHERA (lutetium Lu 177 dotatate) |